Huaye Lu, Lei Han, Peihong Wu, Xin Liu, Qingtao Jiang
{"title":"Disease burden and trends of lung cancer attributable to nickel among Chinese and global population: a cross-sectional study.","authors":"Huaye Lu, Lei Han, Peihong Wu, Xin Liu, Qingtao Jiang","doi":"10.3389/fmed.2024.1497597","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Nickel is a well-established carcinogen, and China stands as a significant producer of nickel compounds. Nickel-associated lung cancer is increasingly acknowledged as a pressing public health concern. This study presents a comprehensive analysis at temporal, spatial, and population levels utilizing the most recent data from GBD 2019 to estimate the disease burden of nickel-associated lung cancer from 1990 to 2019, and make predictions to 2035.</p><p><strong>Methods: </strong>We delineated data on nickel-associated lung cancer concerning mortality, disability-adjusted life years (DALY), and age-standardized rates (ASRs) over a 30-year period based on the global burden of disease (GBD) 2019. Joinpoint regression analysis was utilized to identify temporal changes and to estimate the annual percentage change (APC) as well as the average annual percentage change (AAPC) for each trend segment. The Nordpred model was employed to elaborate on ASRs trends from 1990 to 2019, along with projections for the subsequent 15 years.</p><p><strong>Results: </strong>In both China and globally, the mortality rate from nickel-associated lung cancer and the associated DALYs have increased by 145.8, 77.8, 120.2, and 64.6%, respectively. ASRs within Chinese and global populations exhibit a pattern characterized by an initial increase followed by a decrease as age progresses, with males higher than females. The trend for DALY indicates an initial rise followed by a decline, peaking in the year 2027.</p><p><strong>Conclusion: </strong>The age structure of nickel-associated lung cancer patients shows an aging trend, and the ASDR in the Chinese population indicates a potential upward trend when projecting the disease burden of nickel-associated lung cancer over the next 15 years. We should place greater emphasis on the implementation of preventive strategies and the enhancement of the quality of life for current sufferers.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"11 ","pages":"1497597"},"PeriodicalIF":3.1000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695296/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2024.1497597","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Nickel is a well-established carcinogen, and China stands as a significant producer of nickel compounds. Nickel-associated lung cancer is increasingly acknowledged as a pressing public health concern. This study presents a comprehensive analysis at temporal, spatial, and population levels utilizing the most recent data from GBD 2019 to estimate the disease burden of nickel-associated lung cancer from 1990 to 2019, and make predictions to 2035.
Methods: We delineated data on nickel-associated lung cancer concerning mortality, disability-adjusted life years (DALY), and age-standardized rates (ASRs) over a 30-year period based on the global burden of disease (GBD) 2019. Joinpoint regression analysis was utilized to identify temporal changes and to estimate the annual percentage change (APC) as well as the average annual percentage change (AAPC) for each trend segment. The Nordpred model was employed to elaborate on ASRs trends from 1990 to 2019, along with projections for the subsequent 15 years.
Results: In both China and globally, the mortality rate from nickel-associated lung cancer and the associated DALYs have increased by 145.8, 77.8, 120.2, and 64.6%, respectively. ASRs within Chinese and global populations exhibit a pattern characterized by an initial increase followed by a decrease as age progresses, with males higher than females. The trend for DALY indicates an initial rise followed by a decline, peaking in the year 2027.
Conclusion: The age structure of nickel-associated lung cancer patients shows an aging trend, and the ASDR in the Chinese population indicates a potential upward trend when projecting the disease burden of nickel-associated lung cancer over the next 15 years. We should place greater emphasis on the implementation of preventive strategies and the enhancement of the quality of life for current sufferers.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world